Highlights Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Delayed Nasdaq Other stock markets 12:06:10 2024-04-29 pm EDT			5-day change	1st Jan Change
9.746 ^USD	+3.90%		+0.68%	-11.00%

Apr. 16	Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	MT
Apr. 16	Transcript : Precision BioSciences, Inc. - Special Call

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	Apr. 16	MT
Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	Apr. 16	CI
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M	Mar. 27	MT
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	Mar. 06	CI
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	Feb. 20	CI
Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness	Feb. 14	CI
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program	Jan. 09	MT
TG Therapeutics, Inc. Announces Global License Agreement with Precision BioSciences, Inc. for the Development and Commercialization of Precision?s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases	Jan. 09	CI
Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure	Dec. 13	CI
Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases	Dec. 04	CI
Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD?s The Liver Meeting 2023	Nov. 13	CI
Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q3 Revenue $13.1M	Nov. 07	MT
Precision BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
US FDA Transfers Cancer Medication Application to Imugene	23-09-28	MT
Precision BioSciences Says it Received Notice of Allowance for US Patent Covering Treatment for Mitochondrial Diseases	23-09-27	MT
Imugene Secures License for Cell Therapy Program	23-08-16	MT
Precision BioSciences Completes License Deal With Imugene for Cancer Therapy Candidate Azer-Cel	23-08-16	MT
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer	23-08-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Highlights

Filters